Positron system to offer Amyvid PET scans

| | Health Imaging | Molecular Imaging
Positron is using its Attrius system at Caring Heart and Brain Imaging of Manasquan, N.J., which now offers Amyvid PET scans to identify the presence of plaque in the brain, which has been shown to be a precursor to Alzheimer's disease (AD).

Amyvid (Florbetapir F-18 Injection) is indicated for PET imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for AD and other causes of cognitive decline.

"We are pleased that our Attrius PET system could possibly help with the identification and management of this disease," stated Joseph Oliverio, chief technology officer and director of PET clinical programs of Positron.


Related Content

Experts update AUC for amyloid, tau PET imaging for first time in more than a decade
Repurposed radiotracer lights up treatment-resistant tumors 'like a Christmas tree'
Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage

Around the web

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.